Elixinol Global Share Price Down after Land Purchase Announcement

By ,

At time of writing, Elixinol Global Limited [ASX:EXL] is down 2.43%, trading at $3.21.

It has been a successful year for Elixinol Global with the stock returning 133%:

Elixinol Global Share Price

Source: marketindex.com.au

The latest news out of the company is that it has purchased new land for its proposed manufacturing facility and renamed its Australian medical cannabis company.

Download your free report to learn three of the hottest pot stocks on the ASX right now.

New land, new name for Elixinol’s Australian cannabis operation

As per this morning’s announcement, the land purchased is a ‘unique’ 60 acre lot. Located in the Northern Rivers District of NSW, the planned facility will cover around 5000 square metres on a secured 4.9 acre block within the 60 acre property.

With such a large land purchase, the company now has significant room to expand should the medical cannabis industry take off in Australia.

It is crucial to note however, that the company has yet to receive a manufacturing licence from the Office of Drug Control (ODC), or a local council Development Application approval.

However Elixinol Global’s board thinks that, ‘it is commercially prudent to waive the conditions and to secure this unique asset through its outright purchase.’

This is because, ‘based on the Company’s discussions with the ODC, the Board has no reason to believe that licence approval will not be granted.

Basically they are banking on getting the licenses and approvals they need, so they are ready to go as soon as the license and approval come in.

Today, the stock may be down due to market jitters in the US, a source of much of its revenue.

Managing Director Linda McLeod, noted that,

Although it is disappointing to have not received the licences from the ODC as yet, it is in no way reflective of the quality and robustness of our submissions. We understand that the department is under-resourced and has been unable to assess applications within the time-frame originally suggested. We have not been informed of any reason why our applications would be denied.

The proposed medical cannabis manufacturing operation has been renamed to Nunyara Pharma Pty Ltd. Nunyara is an Indigenous word for ‘to be made well again.

In a brand-new report titled ‘Top Three Pot Stocks for 2019’, Sam Volkering reveals pot players dominating the local and global markets for legal marijuana.

What are Elixinol’s prospects going forward?

Elixinol Global has been the star amongst Aussie ‘pot stocks’ for a number of reasons.

For starters, the company has been expanding rapidly, with operations in the US driving their strong cash balance through sales of hemp based products such as snack bars, dietary supplements and skin care products.

Their most recent figures state their cash balance stands at $42.9 million.

Elixinol Share Price

Source: Elixinol Global

So with strong cash flow comes the potential for further expansion.

They also have a diverse product range which appeals to a variety of customers ­­­— they even have CBD dog treats.

Going forward, the company is confident (as the land purchase indicates) of securing an ODC manufacturing license, which would allow it to properly launch its Australian business.

It has also recently expanded into New Zealand and European market.

For the moment, Elixinol’s rise looks hard to stop.


Lachlann Tierney
For Money Morning

PS: Interested in pot stocks? We have an in depth look at three cannabis plays on the ASX in our free report which can be downloaded here. Some of them may surprise you.

About Lachlann Tierney

Lachlann Tierney is an Analyst for Money Morning and has been investing for nearly a decade. With a Masters of Science from the London School of Economics, he brings a sound understanding of global markets to his writing. Lachlann is interested in emerging technologies, energy solutions and helping people invest…

Incannex Healthcare Shares Up on Arthritis Treatment Test (ASX:IHL)

Incannex Healthcare share price [ASX:IHL] is up today after its ASX update shows positive results from IHL’s arthritis treatment test. The Incannex share price is up 9.7% as of 3:00pm today…

Elixinol Share Price Up 12% after Acquiring CannaCare Health (ASX:EXL)

Elixinol Global Ltd [ASX:EXL] share price is up today after agreeing to acquire Germany’s leading CBD brand. The EXL share price is now up 25% YTD, but still down from the 52-week high of 47.5 cents.

Elixinol Share Price Gets Small Boost on Turnaround (ASX:EXL)

After a ripper period in early 2019, the Elixinol Global Ltd [ASX:EXL] share price went on a long-term slide. On a day where the EXL share price was up 3.33% to trade at 15.5 cents, we take a look at the numbers from EXL quarterly update…

Elixinol Share Price Down: Two Thoughts on its Future

After going to almost $6 a share, it is going for almost a tenth of this price today. We look at what has happened to the Elixinol share price and the company’s restructure.

Why ASX Cannabis Stocks are Down — Should You Invest?

It’s been a tough year for ASX cannabis stocks with many companies shedding value over a 12-month window. Only Althea has emerged from the last year with a gain to show for it. It’s worth taking a look at the ETFMG Alternative Harvest ETF chart to see what’s happening to cannabis stocks globally….

Elixinol Share Price Up as US Warms to Cannabis (ASX: EXL)

Cannabis and hemp are back in the US headlines. And one local pot stock — Elixinol — is feeling a high…share price. At time of writing Elixinol Global Ltd [ASX:EXL] is up 11%. Though it did peak even higher at a 12.28% gain prior in early trading…